Donor insulin use predicts beta‐cell function after islet transplantationCitation formats

  • External authors:
  • Angela Summers
  • Petros Yiannoullou
  • Hussein Khambalia
  • Catherine Fullwood
  • John Casey
  • Shareen Forbes
  • Miranda Rosenthal
  • Prv Johnson
  • P Choudhary
  • James Bushnell
  • James Am Shaw
  • D Van Dellen

Standard

Donor insulin use predicts beta‐cell function after islet transplantation. / Shapey, Iestyn M; Summers, Angela; Yiannoullou, Petros; Khambalia, Hussein; Fullwood, Catherine; Hanley, Neil A; Casey, John; Forbes, Shareen; Rosenthal, Miranda; Johnson, Prv; Choudhary, P; Bushnell, James; Shaw, James Am; Augustine, T; Rutter, Martin K; Van Dellen, D.

In: Diabetes, Obesity and Metabolism, 25.05.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Shapey, IM, Summers, A, Yiannoullou, P, Khambalia, H, Fullwood, C, Hanley, NA, Casey, J, Forbes, S, Rosenthal, M, Johnson, P, Choudhary, P, Bushnell, J, Shaw, JA, Augustine, T, Rutter, MK & Van Dellen, D 2020, 'Donor insulin use predicts beta‐cell function after islet transplantation', Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14088

APA

Shapey, I. M., Summers, A., Yiannoullou, P., Khambalia, H., Fullwood, C., Hanley, N. A., Casey, J., Forbes, S., Rosenthal, M., Johnson, P., Choudhary, P., Bushnell, J., Shaw, J. A., Augustine, T., Rutter, M. K., & Van Dellen, D. (2020). Donor insulin use predicts beta‐cell function after islet transplantation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14088

Vancouver

Shapey IM, Summers A, Yiannoullou P, Khambalia H, Fullwood C, Hanley NA et al. Donor insulin use predicts beta‐cell function after islet transplantation. Diabetes, Obesity and Metabolism. 2020 May 25. https://doi.org/10.1111/dom.14088

Author

Shapey, Iestyn M ; Summers, Angela ; Yiannoullou, Petros ; Khambalia, Hussein ; Fullwood, Catherine ; Hanley, Neil A ; Casey, John ; Forbes, Shareen ; Rosenthal, Miranda ; Johnson, Prv ; Choudhary, P ; Bushnell, James ; Shaw, James Am ; Augustine, T ; Rutter, Martin K ; Van Dellen, D. / Donor insulin use predicts beta‐cell function after islet transplantation. In: Diabetes, Obesity and Metabolism. 2020.

Bibtex

@article{60e9b00116444b36b7a6642722372121,
title = "Donor insulin use predicts beta‐cell function after islet transplantation",
abstract = "Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri‐transplant period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts beta‐cell dysfunction after islet transplantation. We reviewed data from the United Kingdom (UK) Transplant Registry and the UK Islet Transplant Consortium – all first‐time transplants between 2008–2016 were included. Linear regression models determined associations between DIU, median and coefficient of variation (CV) peri‐transplant glucose levels and 3‐month islet graft function. In 91 islet cell transplant recipients, DIU was associated with lower islet function assessed by BETA‐2 scores (β [SE] ‐3.5 [1.5], p = 0.02), higher 3‐month post‐transplant HbA1c levels (5.4 [2.6] mmol/mol, p = 0.04) and lower fasting c‐peptide levels (−107.9 [46.1] pmol/l, p = 0.02). Glucose at 10512 time points were recorded during the first 5 days peri‐transplant ‐ the median (IQR) daily glucose level was 7.9 (7.0–8.9) mmol/L and glucose CV: 28 (21–35)%. Neither median glucose levels nor glucose CV predicted outcomes post‐transplantation. Data on DIU predicts beta‐cell dysfunction 3‐months after islet transplantation and could help improve donor selection and transplant outcomes.",
author = "Shapey, {Iestyn M} and Angela Summers and Petros Yiannoullou and Hussein Khambalia and Catherine Fullwood and Hanley, {Neil A} and John Casey and Shareen Forbes and Miranda Rosenthal and Prv Johnson and P Choudhary and James Bushnell and Shaw, {James Am} and T Augustine and Rutter, {Martin K} and {Van Dellen}, D",
year = "2020",
month = may,
day = "25",
doi = "10.1111/dom.14088",
language = "English",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "John Wiley & Sons Ltd",

}

RIS

TY - JOUR

T1 - Donor insulin use predicts beta‐cell function after islet transplantation

AU - Shapey, Iestyn M

AU - Summers, Angela

AU - Yiannoullou, Petros

AU - Khambalia, Hussein

AU - Fullwood, Catherine

AU - Hanley, Neil A

AU - Casey, John

AU - Forbes, Shareen

AU - Rosenthal, Miranda

AU - Johnson, Prv

AU - Choudhary, P

AU - Bushnell, James

AU - Shaw, James Am

AU - Augustine, T

AU - Rutter, Martin K

AU - Van Dellen, D

PY - 2020/5/25

Y1 - 2020/5/25

N2 - Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri‐transplant period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts beta‐cell dysfunction after islet transplantation. We reviewed data from the United Kingdom (UK) Transplant Registry and the UK Islet Transplant Consortium – all first‐time transplants between 2008–2016 were included. Linear regression models determined associations between DIU, median and coefficient of variation (CV) peri‐transplant glucose levels and 3‐month islet graft function. In 91 islet cell transplant recipients, DIU was associated with lower islet function assessed by BETA‐2 scores (β [SE] ‐3.5 [1.5], p = 0.02), higher 3‐month post‐transplant HbA1c levels (5.4 [2.6] mmol/mol, p = 0.04) and lower fasting c‐peptide levels (−107.9 [46.1] pmol/l, p = 0.02). Glucose at 10512 time points were recorded during the first 5 days peri‐transplant ‐ the median (IQR) daily glucose level was 7.9 (7.0–8.9) mmol/L and glucose CV: 28 (21–35)%. Neither median glucose levels nor glucose CV predicted outcomes post‐transplantation. Data on DIU predicts beta‐cell dysfunction 3‐months after islet transplantation and could help improve donor selection and transplant outcomes.

AB - Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri‐transplant period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts beta‐cell dysfunction after islet transplantation. We reviewed data from the United Kingdom (UK) Transplant Registry and the UK Islet Transplant Consortium – all first‐time transplants between 2008–2016 were included. Linear regression models determined associations between DIU, median and coefficient of variation (CV) peri‐transplant glucose levels and 3‐month islet graft function. In 91 islet cell transplant recipients, DIU was associated with lower islet function assessed by BETA‐2 scores (β [SE] ‐3.5 [1.5], p = 0.02), higher 3‐month post‐transplant HbA1c levels (5.4 [2.6] mmol/mol, p = 0.04) and lower fasting c‐peptide levels (−107.9 [46.1] pmol/l, p = 0.02). Glucose at 10512 time points were recorded during the first 5 days peri‐transplant ‐ the median (IQR) daily glucose level was 7.9 (7.0–8.9) mmol/L and glucose CV: 28 (21–35)%. Neither median glucose levels nor glucose CV predicted outcomes post‐transplantation. Data on DIU predicts beta‐cell dysfunction 3‐months after islet transplantation and could help improve donor selection and transplant outcomes.

U2 - 10.1111/dom.14088

DO - 10.1111/dom.14088

M3 - Article

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -